Mumbai, Oct. 30 -- Sun Pharmaceutical Industries announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA(R) (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA).

Published by HT Digital Content Services with permission from Capital Market....